Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

UAT Group Strategic Partner Next Casting Receives Patent

Umbra Applied Technologies Group, Inc.

Umbra Applied Technologies Group, Inc. (UAT Group) (OTC: UATG ) - UAT Group strategic partner Next Casting Technologies has been issued a patent for technology it developed for use in its advanced SmartCast, IntelliBrace and BioSplint products. Filed in December of 2017, this patent was one of four patents that had been pending. The Company anticipates remaining patents being approved over the next ten to twelve months. Next Casting Technologies (NCT) has begun the process of commercializing proprietary technologies which will positively impact people’s lives and increase value through a unique and diverse product line. The SmartCast Application allows the casting technician to slip the SmartCast around the affected limb and position to ﬁt by using a simple “mold and hold” technique. Lastly, the cast is activated by pressing the button to initiate the curing process. Within 4 minutes that cast is hardened, fixed in place and is not dependent on the technician’s artistry, or lack thereof. The results are a predictable standard of care across the patient spectrum. The end result is a completely waterproof, antimicrobial, orthopedic cast, that is time saving for clinicians and a superior standard of care for patients. UAT Group’s Chief Executive Officer Alex Umbra, stated, “This marks a significant step forward for NCT. Having the appropriate measures in place to protect intellectual property enables the Company to begin evaluating production schedules, supply chain resources and fulfillment execution strategies. I look forward to working with the NCT team in the near-term future as they begin their ramp up.” UAT Group has a 26% equity interest in NCT. For more information about NextCast go here: https://nextorthocast.com/ For more information about UAT go here: http://umbraappliedtechnologies.com/ About Umbra Applied Technologies Group, Inc. The firm is located in Tampa, Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details UAT Group info@uatgroup.com

May 26, 2023 08:00 AM Eastern Daylight Time

Poolbeg Pharma's new NED looking at "new opportunities" for the business

Poolbeg Pharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 26, 2023 07:32 AM Eastern Daylight Time

Video

New Products, Growth - USMJ.com Memorial Day Sale

North American Cannabis Holdings, Inc.

North American Cannabis Holdings, Inc. (OTC: USMJ) - USMJ.com a leading cannabis-focused e-commerce site, is thrilled to announce several exciting updates that will delight cannabis enthusiasts across the country. With a commitment to providing high-quality products and exceptional customer service, USMJ continues to be a trusted destination for cannabis enthusiasts nationwide. Remembering and Honoring Our Fallen Heroes: USMJ first and foremost recognizes the significance of Memorial Day and the sacrifices made by our military heroes. In remembrance of those who have selflessly served our nation, USMJ pays tribute to their courage, dedication, and ultimate sacrifice. It is with deep gratitude that USMJ takes this opportunity to honor these fallen heroes and express sincere appreciation for their service. USMJ also provides a special Veterans program with discounts for all who have served. Follow a simple application process to enroll. 20% Off Your Order of $50 or More: USMJ understands the importance of value for its customers. To show appreciation for their continued support, USMJ is offering an exclusive limited-time promotion. Customers can now enjoy a generous discount of 20% on orders totaling $50 or more. This incredible offer allows cannabis enthusiasts to explore a wide range of products while saving on their purchases. The promotion is a week-long and kicked off Wednesday, May 24, 2023, with special notifications delivered to the core customer base ahead of this announcement. The promotion is set to end May 31, 2023, @ 11:59 PM. Use discount code MEM20 at checkout to get 20% off your order. Introducing New Delta 8 Gummies from Wasatch Hemp: USMJ is excited to introduce the latest addition to its product lineup – the highly anticipated Delta 8 Gummies from Wasatch Hemp. These delicious gummies are infused with Delta 8, a hemp-derived cannabinoid known for its unique properties. Crafted with care and precision, the Delta 8 Gummies offer a convenient and enjoyable way to experience the benefits of Delta 8. With Wasatch Hemp's commitment to quality and USMJ's dedication to offering exceptional products, customers can expect nothing short of excellence. Growing Vendor Base and New Products Coming On Board: USMJ is constantly striving to provide an extensive selection of high-quality cannabis products to its customers. To achieve this, USMJ is actively expanding its vendor base and welcoming new products on board. By collaborating with trusted and reputable vendors, USMJ ensures that customers have access to a diverse range of top-tier cannabis products. This commitment to growing the vendor base underscores USMJ's dedication to offering the latest and most innovative products in the industry. USMJ remains dedicated to delivering exceptional customer experiences and upholding the highest standards in the cannabis industry. Through these exciting updates, USMJ aims to provide cannabis enthusiasts with the best products, unbeatable discounts, and an ever-expanding selection of premium offerings. Background: USMJ.com is a line of business of North American Cannabis Holdings, Inc. USMJ.com is one of the largest and fastest-growing marketplaces to shop for CBD, CBG, hemp and cannabis essentials. Additionally, UMSJ.com has multiple B2B programs and partnerships offering them access to the tools and products USMJ.com has to offer. Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For More Information Contact Steven Rash North American Cannabis Holdings, Inc +1 888 694 8765 info@shopusmj.com Contact Details: USMJ info@shopusmj.com Company Website Contact Details USMJ info@shopusmj.com Company Website https://usmj.com/

May 25, 2023 08:45 AM Eastern Daylight Time

M2Bio Sciences Division M2Biome Cardiometabolic Health Launches Website

Institute of Biomedical Research Corp.

Institute of Biomedical Research (OTC: MRES) ("M2Bio Sciences'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: M2Biome, a division of M2Bio Sciences, is pleased to announce the launch of its website. The website has been set up to serve healthcare professionals and health consumers alike. Sections include a health blog, called ‘Digestible Facts’, educational resources, recipes, and more. One key feature of the website includes a diabetes screening tool on the home page, which will notify people of their risk of having undiagnosed type 2 diabetes (T2DM) and prompt them to undergo further tests. This is also a valuable tool for highlighting the lifestyle changes that are needed to reduce the risk of developing T2DM and other non-communicable diseases that have similar underlying pathophysiology. Part of the M2Biome mission is to provide education on health and nutrition, and create awareness of the risk of disease. “The prevalence of undiagnosed diabetes in South Africa is estimated to be in the region of 45%. Unfortunately, many people are only diagnosed once they have developed complications, which has a huge impact on the quality of life and the cost of managing these individuals. As type 2 diabetes is largely preventable and manageable, I am passionate about creating awareness of risk. I am currently working on further validating the African Diabetes Risk Score to make it more generalizable in the South African population. ”, says Nicola Royce, Managing Director of M2Biome. The recipe section will be the ultimate user-friendly guide to very practical and easy-to-prepare healthy dishes. Each recipe will also serve as an opportunity to educate on the nutritional content of the dish. You will also learn how to make use of simple cooking methods to get the most out of the least ingredients. The recipes are divided into breakfast, lunch, dinner, dessert, snacks, condiments, and drinks for easy access to your needs. Icons have been developed to guide you in meeting your special dietary requirements with confidence. "Food should be fun, functional, and user-friendly. If you cannot make it, you cannot eat it. It is unacceptable for good produce to go to waste because it is too difficult to make the most of it. Never should any ingredient be used or abused to end up being unhealthy. Cooking should be easy and done in such a way that the end result is multi-beneficial. ", says Wilna Eksteen, Cardiometabolic Product Developer. M2Biome is also developing a Registered Dietitian database for health consumers to seek individualized treatment. While there are some basic principles when it comes to nutrition, there is no ‘blanket’ approach when applying medical nutrition therapy for various conditions. It is important for people to consult a Registered Dietitian to receive an individualized and tailored approach that takes religious requirements, life cycle stage, and dietary requirements and preferences into account. ‘’In line with an individualized approach, M2Biome will be incorporating Artificial Intelligence and Machine Learning for better patient outcomes. Machine learning takes large amounts of data to uncover patterns and insights related to dietary choices, health outcomes, and nutritional needs. Leveraging machine learning algorithms assists with developing personalised nutrition recommendations based on individual factors such as age, gender, activity level, and health conditions, leading to more tailored and effective dietary interventions. This will all be incorporated into an interactive model that assists individuals with ‘health nudges’ by generating meal plans, recipes to go with these meal plans, and even recommendations of where and what to eat, based on their requirements. Individuals can insert their daily activities, which will be documented and made available to their healthcare practitioners. Any health developments are recorded, which assists with adjusting recommendations and advising on any drug and nutrient interactions that should be remedied. This is all really the tip of the iceberg, and the sky appears to be the limit with all of the ‘smart’ technology we have in our lives today and how it can be used to connect the dots to help us lead healthier lives. This new interactive platform is going to be epic!’’ says Jeff Robinson, M2Bio Sciences CEO. About Institute of Biomedical Research Corp./ DBA M2Bio Sciences Institute of Biomedical Research Corp, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES". Contact: Website: www.m2biome.com E-mail: m2biome@m2bio.co Phone: +27 72 333 2148 Visit us on social media: Facebook Twitter LinkedIn Instagram Forward-Looking Statements: Safe Harbour Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences to include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements. Contact Details Institute of Biomedical Research Corp. m2biome@m2bio.co Company Website http://www.m2biome.com/

May 25, 2023 08:30 AM Eastern Daylight Time

News Release

HealthLynked 1Q financial results highlighted by impressive revenue growth and healthcare innovation

HealthLynked

HealthLynked's Dr Michael Dent and George O'Leary join Natalie Stoberman from the Proactive studios to discuss the company's first-quarter financial results. O'Leary and Dent say HealthLynked has experienced 15% year-over-year revenue growth in addition to 25% revenue growth between quarters. Both say the increases are driven by their subsidiaries and the introduction of online concierge services. O'Leary adds other key factor that highlight the company's reported earnings include increased revenue, decreased operating loss, and gains from the sale of their ACO division. Both Dent and O'Leary say HealthLynked aims to expand its core business and achieve profitability by the end of the year. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

May 24, 2023 02:51 PM Eastern Daylight Time

Video

News Release

Voyageur Pharmaceuticals partners with Rain Cage to develop nanocarbon-based radiology drugs

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals CEO Brent Willis join's Proactive's Natalie Stoberman to share a significant licensing agreement with Rain Cage Carbon to develop nanocarbon-based contrast drugs for medical imaging. Willis says the partnership aims to develop new contrast agents for the radiology drug market while also making Voyageur the first carbon-neutral pharmaceutical company in the industry. He explains that Rain Cage Carbon's innovative technology allows Voyageur to extract carbon dioxide and other emissions, generating high-grade carbon for various applications. By leveraging this technology, Willis says Voyageur plans to create safer and more effective drugs using carbon 60 molecules. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

May 24, 2023 02:22 PM Eastern Daylight Time

Video

News Release

Delivra Health Brands achieves positive EBITDA results for second consecutive quarter

Delivra Health Brands Inc.

Delivra Health Brands President and CEO Gord Davey joins Natalie Stoberman from the Proactive studios to share the how the company's 3Q financial and operational results have been able to repeat positive EBITDA for the second straight quarter. Davey says the company's focus on increasing revenue, reducing costs, and improving margins has been the driver in steady growth and recording a positive EBITDA performance. Davey adds Delivra continues to execute its strategies by expanding its business in the U.S. and international markets, introducing new products in both Dream Water and LivRelief lines, and investing in marketing efforts and ongoing innovation. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

May 24, 2023 02:00 PM Eastern Daylight Time

Video

Inhibikase Therapeutics: A Novel And Promising Approach To Neurodegeneration And Oncology

TalkMarkets on IKT

Inhibikase Therapeutics ( IKT ) is a small capitalization company working in both neurology and oncology. Their principal focus is a small molecule inhibitor of c-Abl for the treatment of a number of neurodegenerative disorders with an initial focus on Parkinson’s Disease. The lead asset (IkT-148009) is a selective, brain penetrant inhibitor of c-Abl1 and Abl2/ARG. The drug is designed to minimize the toxicity commonly associated with the cancer drugs of this class, while maximizing efficacy against neurological diseases. Neurodegeneration has multiple causes, but the aggregation of misfolded proteins is often associated with these diseases and in the case of Parkinson’s Disease it is the aggregation of alpha-synuclein. Given that these aggregates are clearly associated with the disease, a common tactic to drug development is to find treatments that eliminate the protein bundles, but these approaches have generally had quite modest effects. Inhibikase approaches the disease from a different perspective in that the core issue is when those aggregates become internalized in neurons (in the case of PD). When this occurs, c-Abl triggers a cascade of responses that ultimately leads to neurodegeneration. Inhibiting c-Abl stops these reactions and saves the neurons. (The details of this approach can be seen in the recent article in Neurodegenerative Disease ). One of the difficulties of inhibiting c-Abl in neurodegenerative diseases, however, is the potential toxicity. Gleevec is a commonly used inhibitor of c-Abl in oncology, where it has an acceptable toxicity profile, but it would be too toxic for neurological indications. Developing a drug that can inhibit c-Abl in the brain but without the common toxicities is the fundamental breakthrough of IkT-148009. It is the selectivity of the inhibition that is key. The corporate presentation clearly shows a differentiated inhibition profile ( source ). This selective inhibition of IkT-148009leads to a very clean toxicity profile ( see graphic ). This safety is not simply theoretical as their phase I, Ib, and 2a trials confirm the lack of significant toxicity. There was a grand total of 14 reported adverse events among 113 treated patients and only one was moderate; the rest were mild ( see graphic ). It cannot be stressed enough that safety is absolutely crucial in neurological indications, and it seems that the design of the drug, the preclinical and early clinical results all point to low toxicity, which is exactly what you want to see from these early looks. Inhibikase currently has an ongoing double-blind enrollment trial across three doses for the treatment of Parkinson’s disease. The trial includes a 3-month treatment period followed by a 12-month open label extension. The primary endpoint is safety, which is appropriate for a dose ranging phase II trial and expectations should be a clear confirmation of the established safety profile. That being said, there is a robust set of secondary endpoints that will provide important information as to the efficacy profile. The preclinical work in a Parkinson disease animal model demonstrated a consistent efficacy where treatment lowered alpha-synuclein back to baseline levels, preserved as much as 85% of neurons, restored as much as 90% of motor function, and suppressed neuroinflammation back to near baseline levels. Obviously, a replication of those results in the phase II trial would be spectacular but a clear win would also be a confirmation of the safety profile, a strong signal of efficacy, and a clear move forward dosing level. Given that the PK profile seen in the animal models is similar to the PK shown in the phase I trials, the chosen dosing levels in the phase II trial should lead to a go forward dosing as well as a demonstration of efficacy. The company has guided to a robust set of progress in 2023, where the continued enrollment of the phase II trial is perhaps the most important. Open up to thirty-five 201 trial sites by close of 2Q23 Active screening of commercial formulation Implement 12-month open-label safety extension study into 201 trial Characterize novel compounds as follow-ons to IKT-148009 I noted earlier that Inhibikase Therapeutics is both a neurology and oncology company. In terms of oncology, the company has an improved version of Gleevec that is designed to minimize GI toxicity. This asset is undergoing a bioequivalence trial, which could accelerate the pathway to approval, but I think the key valuation inflection point will be the 201 trial in Parkinson’s disease. The 201 trial has the potential to confirm the safety profile, identify a go-forward dose, and establish efficacy. The current valuation of the company does not reflect any of that potential. It does not even properly reflect the safety profile seen in the phase I trials let alone a potential success in the 201 trial. The heavily discounted valuation provides a compelling risk/reward given the ability to establish both safety and efficacy in Parkinson’s disease let alone any progress in oncology. Originally published at TalkMarkets. More By This Author: The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach? Coya Therapeutics: Another Success Sarepta: The AdCom Documents Enter The Discussion Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and otherwise represent their own assessments and opinions. Authors are not compensated by the subject companies in any way. This article is also part of our IR Insights Initiative in which articles about participating companies can receive greater visibility. To learn more click here. Contact Details TalkMarkets ir@talkmarkets.com

May 24, 2023 12:04 PM Eastern Daylight Time

ImmuPharma "looking forward with quiet confidence" to FDA response

ImmuPharma PLC

Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 24, 2023 11:08 AM Eastern Daylight Time

Video

1 ... 121 122 123 124 125 ... 305